This targeted hyperthermia treatment enables localized, minimally invasive thermal treatment for solid tumours and gynecologic disorders
Background Conventional treatments for several cancers and gynecologic disorders may involve surgery, systemic drugs, or energy-based procedures that can adversely affect surrounding healthy tissue. Magnetic hyperthermia offers an approach to target specific tissue and activate therapeutic heat through an external alternating magnetic field. However, commercial adoption has been limited by insufficient heating efficiency, the quantity of nanoparticles required, and challenges in achieving selective tissue accumulation. This technology addresses those limitations through cobalt doping, controlled nanoparticle geometry, high crystallinity, polymer encapsulation, and optional molecular targeting.
Technology Description Researchers at Oregon State University and Oregon Health & Science University have developed cobalt-doped iron oxide nanoparticles designed to generate highly localized heat when exposed to an external alternating magnetic field. The platform combines engineered nanoparticle shape, composition, and surface functionalization to improve heating performance and direct treatment toward selected tissues for a variety of diseases.
The nanoparticles can be encapsulated in biocompatible polymers and conjugated with peptides, antibodies, or other targeting agents. This modular design supports development of minimally invasive therapies for conditions including ovarian cancer and endometriosis. This platform could enable localized, minimally invasive thermal treatment of abnormal tissue while limiting exposure of surrounding healthy tissue. Initial development focuses on ovarian cancer and endometriosis, with broader potential across solid tumors and other conditions that may benefit from targeted tissue ablation. These engineered nanoparticles demonstrated substantially greater heating efficiency than similarly sized spherical nanoparticles in reported laboratory testing, achieving a specific absorption rate exceeding 8,000 W/g, more than 6 times that of comparable spherical nanoparticles. Targeted particles also showed increased cellular heating and reduced endometriosis-cell viability in preclinical experiments, supporting further development for localized treatment of gynecologic diseases.
These results are currently preclinical and do not establish safety or efficacy in humans; additional development is needed.
Further Details:
Features & Benefits
Applications
Opportunity Oregon State University is seeking development partners to collaborate in further clinical investigations, commercialization, and licensing.
Patents